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Could It be Applied for 
Secondary Prevention 
in Patients Undergoing 
Resection for Lung Cancer?
To the Editor:
In the January issue of Journal of 
Thoracic Oncology, Field et al.1 reem-
phasize the recently published results 
of the National Lung Screening Trial 
(NLST) regarding the role of low-
dose spiral computed tomography 
(CT) as a screening modality in heavy 
smokers. The Strategic CT Screening 
Advisory Committee is currently 
engaging professional societies to 
focus on delivering clear guidelines 
and recommendations in this regard. 
Notably, NLST showed that primary 
prevention with low-dose CT in heavy 
smokers led to 20% fewer deaths from 
non–small-cell lung cancer (NSCLC) 
when compared with screening via 
old-fashioned chest radiographs.2 
There is no doubt that recent techni-
cal developments have revolutionized 
CT capabilities and, as a result, its 
clinical applications. However, cost-
effectiveness of this screening modal-
ity and the amount of overdiagnosis 
in the NLST remains to be clarified 
before recommending it for general 
practice.1,2 Confounding comorbidi-
ties and practical hurdles may further 
reduce this screening’s efficacy, as 
89% of smokers will never develop 
lung cancer.
Conversely, it is known that 
20% of completely resected Stage I 
NSCLC patients do develop recur-
rent lung cancer, most commonly 
to the thorax and usually within the 
first years postoperatively.3 The recur-
rence rate more than doubles for the 
FIGURE 1. Multiple skin lesions occurring on right lower quadrant of the abdo-
men. Some tumors have undergone self-destruction and fusion.
FIGURE 2. A, Abdominal CT showing multiple skin lesions in the right lower 
quadrant of the abdomen and tumor infiltration to subcutaneous tissue. B, CT after 
six cycles of gemcitabine, revealing significant reductions to tumors. CT, computed 
tomography.
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operated tumor, node, metastasis 
Stage II NSCLC patients. Therefore, 
an effective secondary prevention is 
imperative in these patients to ensure 
the best outcomes.
Notwithstanding, it has been 
shown that lung cancer patients often 
receive a higher dose of radiation 
with conventional-dose CT than that 
considered safe, which could increase 
significantly their already increased 
lifetime cancer risk.4 As a result, strate-
gies are stringently needed to decrease 
radiation doses during the postopera-
tive follow-up in these patients, the 
majority of whom will never relapse. 
Given the results of NLST, it seems 
that utility of low-dose CT should 
also be tested in these patients who 
have completed curative treatment, 
but who remain at increased risk for 
recurrent disease. Further studies of 
the underlying economic, psychoso-
cial, and physical barriers of low-dose 
CT in this population are probably 
warranted.
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Inevitably Leads to 
Inferior Outcome in 
Combined Modality 
Treatment for 
Unresectable Stage III 
Non-small Cell  
Lung Cancer
To the Editor:
We read with interest the recent 
retrospective report of Chen et al.1 on the 
deleterious effects of delayed initiation 
of radiotherapy (RT) after induction che-
motherapy (CHT) in stage III non-small 
cell lung cancer (NSCLC) due to tumor 
regrowth occurring within a few weeks. 
They have concluded that RT treat-
ment planning should begin as soon as 
possible after the administration of induc-
tion CHT to maximize its benefits and 
provided a volumetric analysis of tumors 
to support their conclusion of acceler-
ated repopulation as the mechanism for 
regrowth during delays. Their results in 
fact reconfirm the study of El-Sharouni 
et al.2 which compared computed tomog-
raphy (CT) scans-based assessment of 
tumor changes before and after induction 
CHT, with an emphasis on the time inter-
val from the last induction CHT cycle 
to the timing of the RT treatment plan-
ning CT scan. They showed that during 
the waiting period (for the planning CT 
scan and start of RT), a total of 41% of all 
tumors became incurable. Bozcuk et al.3 
recently looked at the benefits of induc-
tion CHT before RT in NSCLC using 
a meta-analytical approach with meta-
regression analysis. Using 13 completed 
randomized clinical trials involving a total 
of 2776 patients, they found that the time 
to RT initiation was inversely associated 
with the benefit from induction CHT at 2 
( p = 0.050) and 3 years ( p = 0.093).
As noted by the authors, a range 
of prospective randomized clinical tri-
als followed by recent meta-analyses4 
have confirmed that in unresectable 
stage III NSCLC patients meeting the 
selection criteria for such trials, the 
standard of care is concurrent RT-CHT, 
with CHT initiated on day 1 of RT, as 
compared with sequential CHT fol-
lowed by RT. Furthermore, the recently 
published randomized trial (CALGB 
39801)5 of concurrent RT-CHT with or 
without the addition of induction CHT 
showed that the experimental arm gen-
erated excess toxicity and provided 
no survival benefit over concurrent 
RT-CHT alone.5 With this evidence in 
mind, the present report by Chen et al. 
fails to adequately justify their con-
clusion about future clinical research 
in this setting without clear upfront 
patient and/or tumor selection criteria 
which may prompt an indication for 
the use of induction CHT. In addition, 
they identify “logistical/scheduling 
constraints in 14 of 21 cases” which 
are otherwise not characterized as the 
basis for delays in RT initiation after 
induction. This suggests a number of 
variables in their study population 
which would not conventionally make 
these patients trial eligible. Without 
better character ization of their popula-
tion, it then becomes difficult to under-
stand why one should optimize what 
is already an inferior (i.e., induction 
CHT) approach to managing stage III 
NSCLC but not further optimize the 
better (RT-CHT) approach associated 
with the optimal survival.
We share the authors’ goals in pro-
viding the best care possible for patients 
confronting locally advanced lung can-
cer and agree that optimizing the deliv-
ery of RT is a priority. The old notion of 
“doing something while the patient waits 
for the radiotherapy planning scan” is 
clearly not tenable. A more detailed 
analysis of the clinical circumstances 
in the present series would have further 
served to justify that proposition.
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